Literature DB >> 22999905

Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra.

Olivier Aubert1, Achille Aouba, Soizic Deshayes, Sophie Georgin-Lavialle, Philippe Rieu, Olivier Hermine.   

Abstract

Erdheim-Chester disease is a rare non-langerhans cell histiocytosis characterized by infiltration of foamy CD68-positive but CD1a-negative macrophages and fibro-inflammatory lesions as retroperitoneal, periureteral areas or bones. Interferon-α therapy has been used as treatment but it had variable efficiency and limited tolerance. More recently, a recombinant form of interleukin-1 receptor antagonist (anakinra) was used with success but no skeletal radiological improvement was recorded. We report here a case of interleukin-1 receptor antagonist in the treatment of refractory bones infiltration in Erdheim-Chester disease. After 1 year of treatment, the positron emission tomography-computed tomography showed an outstanding response of the skeletal involvement with clearly lower and smaller hypermetabolism images.
Copyright © 2012 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999905     DOI: 10.1016/j.jbspin.2012.07.005

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  13 in total

Review 1.  Erdheim-Chester Disease: a comprehensive review of the literature.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Yehuda Shoenfeld
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

2.  Erdheim-Chester disease and Schnitzler syndrome: so near, and yet so far.

Authors:  Petr Szturz; Libor Hlavatý; Jiří Prášek; Dana Dvořáková
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Authors:  Eli L Diamond; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Lynn Brody; Maria Arcila; Christian Bowers; Mark Fluchel
Journal:  Blood       Date:  2016-08-17       Impact factor: 22.113

Review 5.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

Review 6.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

7.  Erdheim-Chester disease and knee pain in a dialysis patient.

Authors:  Sibylle Rademacher; Joannis Anagnostopoulos; Friedrich C Luft; Ralph Kettritz
Journal:  Clin Kidney J       Date:  2014-04-04

8.  Erdheim-Chester disease: from palliative care to targeted treatment.

Authors:  Giorgio Graziani; Manuel A Podestà; David Cucchiari; Francesco Reggiani; Claudio Ponticelli
Journal:  Clin Kidney J       Date:  2014-07-15

9.  Perirenal fibrosis: make your diagnosis.

Authors:  M G Zeier; Maxime Samson; Cédric Rossi; Zara Soltani; Frédéric Charlotte; Gilbert Zanetta; Jean-Michel Rebibou
Journal:  Clin Kidney J       Date:  2013-09-05

Review 10.  Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.

Authors:  Giulio Cavalli; Riccardo Biavasco; Bruno Borgiani; Lorenzo Dagna
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.